ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
出版年份 2016 全文链接
标题
ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines
作者
关键词
Gene expression, Protein expression, Cell staining, Hyperexpression techniques, Kinase inhibitors, Tyrosine kinase inhibitors, Cell viability testing, Tyrosine kinases
出版物
PLoS One
Volume 11, Issue 8, Pages e0161470
出版商
Public Library of Science (PLoS)
发表日期
2016-08-19
DOI
10.1371/journal.pone.0161470
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Efficacy of ponatinib against ABL tyrosine kinase inhibitor-resistant leukemia cells
- (2013) Seiichi Okabe et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
- (2013) A. Hochhaus et al. BLOOD
- Interaction of the Efflux Transporters ABCB1 and ABCG2 With Imatinib, Nilotinib, and Dasatinib
- (2013) L N Eadie et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships
- (2012) J. S. Khorashad et al. BLOOD
- Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study
- (2012) F J Giles et al. LEUKEMIA
- Mechanisms responsible for nilotinib resistance in human chronic myeloid leukemia cells and reversal of resistance
- (2012) Aylin Camgoz et al. LEUKEMIA & LYMPHOMA
- Degree of kinase inhibition achievedin vitroby imatinib and nilotinib is decreased by high levels of ABCB1 but not ABCG2
- (2012) Laura N. Eadie et al. LEUKEMIA & LYMPHOMA
- Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line
- (2011) Seiichi Okabe et al. Journal of Hematology & Oncology
- Development of imatinib and dasatinib resistance: dynamics of expression of drug transportersABCB1, ABCC1, ABCG2, MVP, and SLC22A1
- (2011) Marta Gromicho et al. LEUKEMIA & LYMPHOMA
- Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways
- (2011) Carine Tang et al. LEUKEMIA & LYMPHOMA
- Dasatinib versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
- (2010) Hagop Kantarjian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Imatinib resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprograming
- (2010) F Zhao et al. ONCOGENE
- Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations
- (2009) M. C. Muller et al. BLOOD
- Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
- (2009) C Tanaka et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- BCR-ABLGene Expression Is Required for Its Mutations in a Novel KCL-22 Cell Culture Model for Acquired Resistance of Chronic Myelogenous Leukemia
- (2009) Hongfeng Yuan et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Impact of BaselineBCR-ABLMutations on Response to Nilotinib in Patients With Chronic Myeloid Leukemia in Chronic Phase
- (2009) Timothy Hughes et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene expression profiling of imatinib and PD166326-resistant CML cell lines identifies Fyn as a gene associated with resistance to BCR-ABL inhibitors
- (2009) S. Grosso et al. MOLECULAR CANCER THERAPEUTICS
- Lyn regulates BCR-ABL and Gab2 tyrosine phosphorylation and c-Cbl protein stability in imatinib-resistant chronic myelogenous leukemia cells
- (2008) J. Wu et al. BLOOD
- Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
- (2008) F.-X. Mahon et al. CANCER RESEARCH
- Association Between Imatinib-Resistant BCR-ABL Mutation-Negative Leukemia and Persistent Activation of LYN Kinase
- (2008) Ji Wu et al. JNCI-Journal of the National Cancer Institute
- Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib
- (2008) Oliver Hantschel et al. LEUKEMIA & LYMPHOMA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More